BONE BIOLOGICS CORP (BBLG)
US0980705018 - Common Stock
Overall BBLG gets a fundamental rating of 2 out of 10. We evaluated BBLG against 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BBLG as it has an excellent financial health rating, but there are worries on the profitability. BBLG is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BBLG had negative earnings in the past year.
BBLG had a negative operating cash flow in the past year.
BBLG had negative earnings in each of the past 5 years.
BBLG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
BBLG has a worse Return On Assets (-280.22%) than 94.30% of its industry peers.
With a Return On Equity value of -307.63%, BBLG is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -280.22% | ||
| ROE | -307.63% | ||
| ROIC | N/A |
ROA(3y)-93.64%
ROA(5y)N/A
ROE(3y)-119.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BBLG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, BBLG has more shares outstanding
Compared to 5 years ago, BBLG has more shares outstanding
BBLG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
BBLG has an Altman-Z score of -39.57. This is a bad value and indicates that BBLG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BBLG (-39.57) is worse than 92.34% of its industry peers.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -39.57 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 11.22 indicates that BBLG has no problem at all paying its short term obligations.
BBLG has a Current ratio of 11.22. This is amongst the best in the industry. BBLG outperforms 83.96% of its industry peers.
BBLG has a Quick Ratio of 11.22. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BBLG (11.22) is better than 83.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.22 | ||
| Quick Ratio | 11.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 91.18% over the past year.
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
BBLG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.27% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.13%
EPS Next 2Y40.23%
EPS Next 3Y25.28%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BBLG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBLG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BBLG's earnings are expected to grow with 25.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.23%
EPS Next 3Y25.28%
5. Dividend
5.1 Amount
No dividends for BBLG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BONE BIOLOGICS CORP
NASDAQ:BBLG (11/18/2024, 8:10:40 PM)
After market: 1.1992 +0.01 (+0.77%)1.19
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.50M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -280.22% | ||
| ROE | -307.63% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.22 | ||
| Quick Ratio | 11.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y95.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y